Update and new trends in antiemetic therapy: the continuing need for novel therapies.
about
Droperidol for treatment of nausea and vomiting in palliative care patientsHaloperidol for the treatment of nausea and vomiting in palliative care patientsA Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingBiological and Pharmacological Aspects of the NK1-ReceptorEvolving treatment paradigms for chemotherapy-induced nausea and vomitingIncidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trialAnticipatory nausea and vomiting due to chemotherapy.Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two pNetupitant PET imaging and ADME studies in humans.Neuropharmacology and management of chemotherapy-induced nausea and vomiting in patients with breast cancer.Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparisonAn assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries.Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting.Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimensMusk shrews selectively bred for motion sickness display increased anesthesia-induced vomiting.Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity.Pharmacogenetics of chemotherapy-induced nausea and vomiting.Investigation of Nausea and Vomiting in Cancer Patients Undergoing ChemotherapyNetupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting.Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.Increased expression of 5-HT3 and NK 1 receptors in 5-fluorouracil-induced mucositis in mouse jejunum.Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron.
P2860
Q24187804-F8A1FE20-789E-432F-8AC4-F642D2819CD8Q24188008-6C58DD2F-8231-419B-AA8A-8A0D41ABBBB8Q26784064-D1FF9F5A-6EF4-459F-98E9-EFAF1697554DQ26784074-67B7B503-7F3A-4A97-BC6B-F4453F368A99Q27024463-B135EDEC-1F3B-45CA-9235-01F5DA0ED848Q30973575-B5C1055C-AB4E-44F1-8F39-45E47248DFDEQ33809584-CBD2E15D-B9F4-4D20-9BED-383854188712Q33809590-AC830834-4A4C-428D-9164-498E27FC550CQ33809595-0D942E05-23E5-4258-AD91-100EABCBC53AQ33866119-8DC98570-E54F-4AE6-BCAD-8FB4812065EAQ34011870-64B164EC-FDFD-4672-95E1-62E3D7F13134Q34038675-D23D7068-1B57-46C7-9F9E-8F7C14E24D84Q34368190-DB09020E-0ACD-4F11-80BD-938AFF8BE409Q34377521-8B0A0346-719F-4043-A58D-66FFA53A8A93Q34403552-1CA98C5E-571F-4A5A-B916-D99B5F66C40CQ35970506-6283DFC9-AA52-4EEA-A2EC-547A19A39CA7Q35980236-387873BB-731C-4619-90A7-02B7C4DC6C23Q36333854-3ABBB8FE-BDE8-4CEB-8E73-9D95A1166068Q36510947-D5748D98-FF1A-40B9-B16A-740D1FD9AFFEQ36639416-5861968F-0028-4155-85F1-57971A8EFE30Q36816419-134DFD6E-E333-4594-B70E-FC44FC3FEA34Q36990036-563C2D62-B870-4932-83FD-7A038AAF1E5FQ37139336-DB2C95DC-3D05-4563-94C0-E853D452E000Q37460036-ACDB7E4D-8509-45AD-B839-908B3A86E167Q37609798-258E9457-00C6-4EF5-B6CE-CC0B9BC3F6C5Q37660556-8B91785F-6F9E-4981-B4A4-FCF52AFDACA8Q38061417-62BFEEC6-D517-4255-8088-0996E9C742E0Q38192940-2D4AB977-23EB-4405-91E6-DDE28CF13E62Q38250191-303A3E3B-943A-4ADE-882E-F1417CC8E093Q38287054-52476088-4ADD-4538-9059-27E0220A5724Q38330216-C7FCB52B-74A8-4337-A2B6-9C60E324E797Q38646159-4886ECA1-446B-425A-94AB-29616DC8EB02Q38650400-8EDACC9A-C873-4E4F-8916-8B4B3D977569Q38739169-F0B54459-5535-4D3D-81FA-5B32D70F92A7Q38943088-73DD1070-EDDF-4083-BC66-32F0C96F081CQ38980779-1DA9B1D6-C5EF-46C5-8020-207AD34C9F8AQ39662535-A259193F-A689-441F-87DD-137DD16F830CQ43471593-F79855B2-D1D8-448D-BAF3-FACA208DA2F0Q45163008-7798FE3B-659E-4297-84C3-3217103B6194Q46044510-CA938B20-5B92-49C5-8F26-E37DFE462E48
P2860
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@ast
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@en
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@nl
type
label
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@ast
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@en
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@nl
prefLabel
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@ast
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@en
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@nl
P2860
P356
P1433
P1476
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
@en
P2093
P2860
P356
10.1093/ANNONC/MDQ600
P577
2010-10-14T00:00:00Z